《生命科学》 2022, 34(4): 409-419

NF-κB在非小细胞肺癌中的作用及治疗研究

朱帅旗¹ , 段海潇¹ , 汪　洋¹ , 胡　翰¹ , 刘滨磊^1,2,*

¹湖北工业大学生物工程与食品学院，武汉 430068 ²武汉滨会生物科技股份有限公司，武汉 436030

摘　要：

核因子-κB (nuclear transcription factor-kappa B, NF-κB) 通过多种信号通路调控细胞生命代谢活动，同时它在非小细胞肺癌(non-small cell lung cancer, NSCLC) 形成、侵袭、转移及血管生成等过程中扮演重要角色。NF-κB 在NSCLC 中处于高度活化的状态已被证实，开发运用NF-κB 抑制剂并联合放化疗等手段治疗NSCLC 患者的策略取得重大进展。此外，NF-κB 通过改变肿瘤微环境(tumor microenvironment, TME) 中免疫/ 炎症细胞的分化与功能，抑制或促进NSCLC 的生长和转移。因此，靶向NF-κB 疗法能够抑制NSCLC 的生长和转移、减少炎性因子的分泌并增强抗肿瘤免疫应答，但也要避免NF-κB 活性的抑制对免疫系统的弱化。该文对NF-κB 在NSCLC 中的作用及治疗研究进行概述。

通讯作者：刘滨磊 , Email:liubl@hbut.edu.cn

Research on the role and treatment of NF-κB in non-small cell lung cancer

ZHU Shuai-Qi¹ , DUAN Hai-Xiao¹ , WANG Yang¹ , HU Han¹ , LIU Bin-Lei^1,2,*

¹Faculty of Bioengineering and Food, Hubei University of Technology, Wuhan 430068, China ²Wuhan Binhui Biotechnology Co., Ltd, Wuhan 436030, China

Abstract:

Nuclear factor-kappa B (nuclear transcription factor-kappa B, NF-κB) regulates cellular metabolism through a variety of signal pathways and plays an important role in the formation, invasion, metastasis, and angiogenesis of non-small cell lung cancer (NSCLC). It has been confirmed that NF-κB is highly activated in NSCLC. Strategies of NF-κB inhibition combined with radiotherapy and chemotherapy for the treatment of NSCLC patients have showed great progress. In addition, NF-κB inhibition would inhibit/promote the growth or metastasis of NSCLC by changing the differentiation and function of immune/inflammatory cells in tumor microenvironment (TME). Therefore, NF-κB targeted therapy can inhibit the growth or metastasis of NSCLC, reduce the secretion of inflammatory factors and enhance anti-tumor immune response. However, it also should be noticed that the NF-κB activity inhibition might weaken the immune system. In conclusion, this article summarizes the role and treatment research related to NF-κB in NSCLC.

Communication Author：LIU Bin-Lei , Email:liubl@hbut.edu.cn